IHAM
GMAB icon

Integral Health Asset Management’s Genmab GMAB Stock Holding History

Integral Health Asset Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,000
Closed -$1.1M – 69
2020
Q3 		$1.1M Buy
+30,000
New +$1.08M 0.34% 67

Other funds holding GMAB

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Integral Health Asset Management's GMAB Position: Q4 2020 in Review

Integral Health Asset Management sold out of Genmab (GMAB) in Q4 2020, closing a stake of 30,000 shares — an estimated $1.1M sold.

Integral Health Asset Management first reported a position in GMAB in Q3 2020 and held it in 1 quarter. The position peaked at $1.1M in Q3 2020. 227 funds tracked by Wall St. Rank hold GMAB as of Q4 2020.

  • Integral Health Asset Management reported no remaining Genmab position as of Q4 2020 after selling out during the quarter.
  • Integral Health Asset Management sold 30,000 Genmab shares in Q4 2020, an estimated $1.1M.
  • Integral Health Asset Management first reported a position in Genmab in Q3 2020 and held it in 1 quarter.
  • Integral Health Asset Management's Genmab position peaked at $1.1M in Q3 2020.
  • 227 funds tracked by Wall St. Rank held Genmab as of Q4 2020.

Based on Integral Health Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.